The N⁶-methyladenosine modification in pathologic angiogenesis

Area of Science:

• Vascular Biology and Medicine
• Epigenetics and RNA Biology

Background:

• The vascular system is crucial for physiological processes, but abnormal blood vessel formation underlies diseases like cancer and ischemic conditions.
• Anti-angiogenic strategies are therapeutic but require deeper mechanistic understanding for enhanced efficacy.
• N6-methyladenosine (m6A) RNA modification is increasingly recognized for its role in regulating vascular development.

Purpose of the Study:

• To review the regulatory role of m6A in various vascular-related diseases.
• To elucidate the mechanisms by which m6A methylation regulators impact angiogenesis in pathological processes.
• To highlight the therapeutic potential of targeting m6A in vascular diseases.

Main Methods:

• Literature review of preclinical and clinical studies on m6A and vascular diseases.
• Analysis of molecular mechanisms linking m6A regulators to angiogenesis.
• Synthesis of current knowledge on m6A's role in cancer, ocular, neurological, and ischemic diseases.

Main Results:

• m6A modification is a critical regulator of vascular development and angiogenesis.
• Dysregulation of m6A pathways contributes to the pathogenesis of major vascular-related diseases.
• Specific m6A regulators influence pathological angiogenesis, offering therapeutic targets.

Conclusions:

• m6A RNA methylation is a significant factor in vascular homeostasis and disease.
• Targeting m6A pathways presents a promising strategy for developing novel anti-angiogenic therapies.
• Further research into m6A mechanisms will advance the treatment of vascular pathologies.